Life science technology company PacBio (NASDAQ:PACB), a developer of advanced sequencing solutions, and microbiome research and discovery specialist Intus Bio announced on Friday the launch of GutID, the first commercial human gut health test powered by PacBio's HiFi sequencing technology and Intus Bio's Titan-1 platform.
GutID is designed to provide a comprehensive and accurate analysis of the gut microbiome, including strain-level identification of both beneficial and pathogenic bacteria.
The test utilises PacBio's long-read sequencing technology, enabling high-resolution analysis of the microbiome and delivering robust and repeatable results.
GutID is targeted at individuals seeking to understand and improve their gut health, and is particularly beneficial for those with conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
The test involves a simple at-home sample collection and provides users with a detailed report, including a microbiome health score and personalised recommendations.
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
BioArctic secures European substance patent for Parkinson's drug candidate exidavnemab
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
1Cell.Ai launches OncoIncytes multi-modal cancer diagnostic panel
Viatris seeks Japanese approval for Effexor for generalised anxiety disorder
Kelun-Biotech's SKB518 granted IND clearance by US FDA
WuXi Biologics completes PPQ campaign at 15,000L production line in Hangzhou
SparX to present Phase 1 clinical update during AACR 2025
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
Clario partners with AWS on advancing clinical data analysis with generative AI
Mezzion Pharmaceuticals welcomes dedicated ICD-10 diagnosis codes for Fontan-associated conditions
TNF Pharmaceuticals showcases isomyosamine's clinical promise at BGS Spring Meeting 2025